Particle.news
Download on the App Store
19 ARTICLES
·
10h ago

AstraZeneca Pledges $50 Billion for U.S. Manufacturing and R&D Expansion

Company executives say the investment will shield U.S. operations from potential import tariffs.

AstraZeneca CEO Pascal Soriot.
A sign is pictured during the unveiling of AstraZeneca's new manufacturing facility, to be operational in the coming months with an initial focus on T-cell therapies, in Rockville, Maryland, U.S., May 5, 2025. REUTERS/Jonathan Ernst/File Photo
Image
Image

Overview

  • AstraZeneca plans to invest $50 billion in the U.S. by 2030 to expand drug manufacturing and research operations.
  • A new facility in Virginia will be the company’s largest single manufacturing investment, focused on weight-management and metabolic drug substances.
  • The plan includes upgrades to R&D centers and cell therapy manufacturing sites in Maryland, Massachusetts, California, Indiana and Texas.
  • Executives frame the move as a safeguard against possible import tariffs threatened by the Trump administration.
  • The expansion is expected to support AstraZeneca’s goal of $80 billion in annual revenue by 2030 and to create tens of thousands of U.S. jobs.